Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc

2
NAS:RIGL (USA)   Ordinary Shares
$ 1.49 +0.07 (+4.93%) 11:09 PM EST
At Loss
Market Cap:
$ 261.31M
Enterprise V:
$ 264.96M
Volume:
679.93K
Avg Vol (2M):
1.22M
Also Trade In:
Volume:
679.93K
At Loss
Avg Vol (2M):
1.22M

Business Description

Rigel Pharmaceuticals Inc logo
Rigel Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
ISIN : US7665596034

Share Class Description:

RIGL: Ordinary Shares
Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Name Current Vs Industry Vs History
Cash-To-Debt 0.94
Equity-to-Asset -0.24
Debt-to-Equity -2.12
Debt-to-EBITDA -3.57
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -14.78
Distress
Grey
Safe
Beneish M-Score -3.46
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 66.98
9-Day RSI 59.54
14-Day RSI 57.36
6-1 Month Momentum % 35.14
12-1 Month Momentum % 12.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.86
Quick Ratio 1.76
Cash Ratio 1.07
Days Inventory 437.5
Days Sales Outstanding 90.31
Days Payable 504.98

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.1
Shareholder Yield % -8.1

Financials (Next Earnings Date:2024-05-02 Est.)

RIGL's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:RIGL

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Rigel Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 116.882
EPS (TTM) ($) -0.14
Beta 0.32
Volatility % 78.57
14-Day RSI 57.36
14-Day ATR ($) 0.091675
20-Day SMA ($) 1.4585
12-1 Month Momentum % 12.78
52-Week Range ($) 0.712 - 1.96
Shares Outstanding (Mil) 175.38

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Rigel Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Rigel Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Rigel Pharmaceuticals Inc Frequently Asked Questions

What is Rigel Pharmaceuticals Inc(RIGL)'s stock price today?
The current price of RIGL is $1.49. The 52 week high of RIGL is $1.96 and 52 week low is $0.71.
When is next earnings date of Rigel Pharmaceuticals Inc(RIGL)?
The next earnings date of Rigel Pharmaceuticals Inc(RIGL) is 2024-05-02 Est..
Does Rigel Pharmaceuticals Inc(RIGL) pay dividends? If so, how much?
Rigel Pharmaceuticals Inc(RIGL) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1